6533b7d5fe1ef96bd126523b

RESEARCH PRODUCT

Booster vaccination after neonatal priming with acellular pertussis vaccine.

Fred ZeppClaire-anne SiegristHeinz-josef SchmittJeanne-marie JacquetDorothee KieningerAlix CollardMarkus KnufClaudius U. Meyer

subject

Whooping CoughFilamentous haemagglutinin adhesinImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesVirusPolio vaccineVaccines AcellularmedicineHumansWhooping coughHepatitis B virusPertussis VaccineDose-Response Relationship Drugbusiness.industryDiphtheriaVaccinationInfant Newbornvirus diseasesInfantmedicine.diseasePrognosisVirologyVaccinationPediatrics Perinatology and Child HealthImmunologybusinessFollow-Up Studies

description

After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/ Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

yearjournalcountryeditionlanguage
2010-04-01The Journal of pediatrics
10.1016/j.jpeds.2009.12.019https://pubmed.ncbi.nlm.nih.gov/20303444